Skip to main content
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. — Investor Relations & Filings

Ticker · EWTX ISIN · US28036F1057 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2024-04-26 Proxy Solicitation & In…
Country US United States of America
Listing US EWTX

About Edgewise Therapeutics, Inc.

https://edgewisetx.com/

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for severe and rare muscle disorders. The company leverages its expertise in muscle science to create precision medicines for conditions including muscular dystrophies and serious cardiac diseases. Its primary goal is to develop treatments that address the underlying causes of these debilitating conditions to improve the lives of patients and their families.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2024-04-26 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, as indicated by the header and references to SEC rules. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals for election of directors, ratification of the independent auditor, and amendments to the certificate of incorporation. The document contains extensive governance information such as board composition, director nominees, committee memberships, and corporate governance guidelines. It is not a full annual report, earnings release, or other financial report but rather a proxy solicitation document intended to inform shareholders and solicit their votes for the annual meeting. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement of its availability.
2024-04-15 English
10-K
Annual Report FY 2023
2024-02-22 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 22, 2024, by Edgewise Therapeutics, Inc. It announces the issuance of a press release regarding financial results for the fourth quarter and full year ended December 31, 2023. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a current report announcing the financial results release. This matches the characteristics of an Earnings Release (ER) announcement filed as a Form 8-K. The document length is 3877 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Earnings Release (ER).
2024-02-22 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.